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Summary
Objectives:  The  treatment  of  sore  throat,  considered  to  be  essentially  due  to  viral  infection,
does not  require  the  use  of  antibiotics.  The  recommended  treatment  is  therefore  based  on
the use  of  topical  anaesthetics  and  antiseptics.  Throat  lozenges  play  a  leading  role  in  topical
treatment  by  allowing  immediate,  massive  and  persistent  release  of  the  active  molecule  at  the
site of  infection.  The  objective  of  this  study  was  to  demonstrate  the  short-term  and  long-term
in vitro  antimicrobial  efﬁcacy  of  Drill® lozenges  in  relation  to  the  main  pathogens  responsible
for upper  respiratory  tract  infections.
Material  and  method:  The  bactericidal  and  virucidal  activity  in  relation  to  the  main  microor-
ganisms responsible  for  upper  respiratory  tract  infections,  including  the  H1N1  inﬂuenza  virus,
was evaluated  after  short  (5  minutes)  and  long  (3  h)  contact  times,  according  to  a  methodology
complying  with  European  standards  for  the  evaluation  of  chemical  antiseptics  and  disinfec-
tants. In  parallel,  the  global  antibacterial  activity  was  determined  on  30  strains  representative
of the  resident  ﬂora  by  determination  of  maximum  inhibitory  dilutions  (MID)  and  maximum
bactericidal  dilutions  (MBD).
Results:  Drill® lozenges  presented  an  antibacterial  activity  inducing  signiﬁcant  (>  90%)  destruc-
tion of  the  main  upper  respiratory  tract  pathogens  after  a  5-minute  contact  time  at  high
concentration  and  after  a  3-hour  contact  time  after  dilution.  Drill® lozenges  also  exerted  an
antiviral activity  inducing  2  log  (99%)  destruction  of  the  H1N1  virus  after  a  5-min  contact  time
at high  concentration,  with  maintenance  of  this  activity  after  dilution  (3  h).  A  homogeneous
antibacterial  activity  was  observed  on  the  resident  ﬂora.
Conclusion:  These  in  vitro  tests  conﬁrm  the  value  of  chlorhexidine  lozenges  in  the  treatment
of upper  respiratory  tract  infections  such  as  sore  throat.
© 2013  Published  by  Elsevier  Masson  SAS.
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ntroduction
n  otorhinolaryngology,  the  term  ‘‘sore  throat’’  is  considered
o  be  a  symptom  corresponding  to  inﬂammation,  fever,  pain
n  swallowing,  cough,  etc.  Many  factors  can  be  responsible
or  sore  throat  (allergy,  smoking,  etc.),  but  the  main  cause
s  infection.  Sore  throat  often  corresponds  to  the  emergence
f  pathogenic  microorganisms  within  a  complex  ecosystem
1—3].  Viral  infection  is  predominant,  justifying  the  current
apid  diagnostic  test  (RDT)  guidelines.  Treatment  of  this
ype  of  disease  still  raises  a  number  of  problems  related  to
ontrol  of  the  emergence  of  multiresistant  bacteria  [4—6],
equiring  limitation  of  the  use  of  antibiotics,  especially
opical  antibiotics,  and  the  concept  of  microbial  ecology
nd  preservation  of  ecosystems.  Viral  infections  generally
esolve  spontaneously  after  several  days  and  the  recom-
ended  treatment  is  essentially  symptomatic  to  relieve
ain.  However,  untreated  bacterial  infections  may  require
edical  consultation  and  the  prescription  of  systemic  antibi-
tics  [7—9].  In  the  light  of  these  various  elements,  the  value
f  a  short  course  (5  days)  of  topical  antiseptics  (mouthwash
r  lozenges)  either  alone  or  in  combination  with  topical
naesthetics,  needs  to  be  reviewed.  Three  recent  in  vivo
tudies  have  demonstrated  the  value  of  antiseptic  sprays,
specially  containing  chlorhexidine,  as  adjuvant  treatment
or  cough  and  viral  or  streptococcal  sore  throat  [10—12]. The
uthors  reported  a  reduction  of  symptoms  and  improvement
f  the  patients’  quality  of  life.  However,  these  studies  did
ot  provide  any  formal  conclusions  on  the  antimicrobial  and
ntiviral  efﬁcacy  of  these  treatments.  The  objective  of  the
resent  study  was  therefore  to  complete  these  studies  by
n  vitro  evaluation  of  the  efﬁcacy  of  Drill® lozenges,  contain-
ng  chlorhexidine  digluconate  (3  mg/lozenge)  and  tetracaine
ydrochloride  (0.2  mg/lozenge),  in:
 short-term  and  long-term  control  of  the  proliferation  of
pathogenic  microorganisms  in  the  upper  respiratory  tract
by  determination  of  speciﬁc  bactericidal  and  virucidal
activities;
 preservation  of  the  upper  respiratory  tract  ecosystem,
limiting  the  risk  of  emergence  of  opportunistic  microor-
ganisms,  by  determination  of  the  antimicrobial  activity  on
a  large  spectrum  of  microorganisms  representative  of  the
upper  respiratory  tract  ﬂora.
aterial and methods
roduct  and  reagents
 Drill® lozenges  (batch  A03007):  1  lozenge  was  diluted  in
2  mL  of  diluent  (stirring  for  1.5  h  at  30 ◦C);
 artiﬁcial  saliva:  aqueous  solution  of  Biotrypcase
(0.25  g/L),  yeast  extract  (0.25  g/L)  (Biomérieux,  France)
autoclaved  at  121 ◦C  for  15  min.  The  following  com-
pounds  (Sigma  Aldrich,  France)  were  dissolved  in  this
solution:  NaCl  (10.2  mM/L),  KCl  (10.7  mM/L),  MgCl2,
6H2O  (0.29  mM/L),  CaCl2,  2H2O  (1.08  mM/L),  KH2PO4
(2.2  mM/L),  K2HPO4 (4.59  mM/L),  NaHCO3 (0.25  mM/L).
The  ﬁnal  solution  was  ﬁltered  on  a  0.45  m  membrane
(Millipore,  USA);
A
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 neutralizing  solution  for  determination  of  bactericidal
activity:  solution  of  polysorbate  80  (10%),  lecithin  (2%),
saponin  (2%)  sodium  thiosulphate  (0.5%)  (Sigma  Aldrich)
q.s.  Trypticase  soy  broth  (Biomérieux).
actericidal  activity  in  relation  to  the  main
athogens  responsible  for  upper  respiratory  tract
nfections
he  short-term  (5  min)  and  long-term  (3  h)  bactericidal
ctivities  against  the  main  pathogens  responsible  for  upper
espiratory  tract  infections  were  determined  according  to
he  guidelines  of  NF  EN  1040  [13], which  deﬁnes  a  loga-
ithmic  reduction  for  a deﬁned  contact  time.  Test  product
oncentrations  corresponded  to  90%,  50%,  10%  and  1%  (V/V)
f  stock  solution  prepared  in  artiﬁcial  saliva  to  mimic  the
onditions  of  use  without  the  effect  of  the  antimicro-
ial  agents  present  in  saliva.  Nine  millilitres  of  solution
ere  placed  in  contact  with  1  mL  of  bacterial  suspension
2  ×  108 bacteria/mL).  Contact  times  tested  at  20 ◦C  were
ve  minutes  and  three  hours  ±  10  seconds,  depending  on
he  concentration.  Concentration/contact  time  pairs  were
elected  in  order  to  simulate  immediate  and  long-term
ffects.  Microorganism/test  product  contact  was  termi-
ated  by  dilution-neutralization.  After  ﬁve  minutes  of
eutralization,  ten  fold  dilutions  were  performed  and  1  mL
f  each  dilution  was  inoculated  onto  agar  (surface  inocula-
ion  in  two  Petri  dishes:  H.  inﬂuenzae  and  B.  catarrhalis) for
etermination  of  the  number  of  colony-forming  units  (CFU).
Reference  strains  corresponding  to  the  main  bacterial
pecies  responsible  for  upper  respiratory  tract  infections
Institut  Pasteur  Collection,  Paris,  France)  and  culture  con-
itions  are  indicated  in  Table  1.
irucidal  activity  in  relation  to  the  inﬂuenza  A
irus (H1N1)
he  short-term  (5  min)  and  long-term  (3  h)  virucidal
ctivity  against  the  H1N1  inﬂuenza  virus  was  deter-
ined  according  to  the  indications  of  NF  EN  14476
14]. The  VR-1520  viral  strain  was  obtained  from
he  ATCC  (American  Type  Culture  Collection,  Molsheim,
rance)  and  ampliﬁed  on  MDCK  cells  (CCL-34,  ATCC)
n  EMEM  medium  (Sigma  Aldrich).  Titration  was  per-
ormed  on  microplates  using  cell  suspensions.  The
ytopathogenic  effect  was  determined  after  48  hours  of
ulture.
Tests  were  performed  under  clean  conditions  (10%
BS:  Sigma  Aldrich)  for  concentrations  of  80%  (possible
eak  concentration),  50%  and  10%  (V/V)  of  stock  solu-
ion  prepared  in  water  for  injections  (Cooper,  France)
or  contact  times  of  5  min  or  3  h  ±  10  s  at  20 ◦C.  The
ction  of  the  product  was  stopped  by  gel  ﬁltration
n  Sephadex  LH  20  (Dutscher)  of  the  10−1 dilution.
ssays  were  performed  on  untreated  cells  and  cells
reated  by  disinfectant  to  conﬁrm  that  subcytotoxic
oncentrations  of  the  disinfectant  did  not  modify  cell  infec-
ivity.
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Table  1  Test  strains  representative  of  upper  respiratory  tract  pathogens  and  culture  conditions  for  determination  of  bactericidal
activity.
Test  strains  Culture  medium  Incubation  conditions
Staphylococcu  aureus  CIP  4.83  Trypticase  soy  agara Aerobic,  36  ±  1 ◦C
Streptococcus  pneumoniae  CIP  104471  Trypticase  soy  agara +  5%  sheep  blooda 5%  CO2, 36  ±  1 ◦C
Streptococcus  pyogenes  CIP  5641  T  Trypticase  soy  agara Aerobic,  36  ±  1 ◦C
Fusobacterium  nucleatum  CIP  101130  Schaedler  agara Anaerobic,  36  ±  1 ◦C
Haemophilus  inﬂuenzae  CIP  102514  T Chocolate  agar  Haemophilusa 5%  CO2, 36  ±  1 ◦C
Branhamella  catarrhalis  CIP  73.21  T Columbia  agar  +  5%  sheep  blooda Aerobic,  36  ±  1 ◦C
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Antibacterial  activity  in  relation  to  the  resident
ﬂora
To  assess  the  impact  of  the  test  product  on  the  upper  respira-
tory  tract  resident  ﬂora,  Maximum  Inhibitory  Dilutions  (MID)
in  relation  to  representative  strains  were  determined  by  the
micromethod  on  liquid  medium.  One  hundred  microlitres
of  broth  were  added  to  each  well  of  a  sterile  96-well
microplate.  One  hundred  microlitres  of  test  solutions  (stock
solution  prepared  in  water  for  injections)  were  added  to
the  ﬁrst  well  of  the  row.  Twofold  serial  dilutions  were  then
performed  from  well  1  to  well  10.  Test  suspensions  of  each
microorganism  were  prepared  extemporaneously  (2  ×  108
bacteria/mL)  and  the  microplate  was  then  inoculated  (Den-
ley  multipoint  inoculator).  After  incubation,  the  MID  was
deﬁned  as  the  highest  dilution  with  no  visible  growth.  Rows
11  and  12  were  used  for  growth  negative  control  and  positive
control,  respectively.  All  tests  were  performed  in  duplicate.
Maximum  Bactericidal  Dilutions  (MBD)  were  determined
by  subculture  of  MID  microplates  on  agar  medium.  After
incubation,  the  MBD  was  deﬁned  such  as  the  highest  dilution
with  no  visible  growth.
Bacterial  strains  were  obtained  from  the  Institut  Pas-
teur  Collection  (Paris)  or  human  isolates.  Culture  media  and
culture  conditions  are  indicated  in  Table  2.
Results
Bactericidal  and  virucidal  activity  in  relation  to  the
main pathogens  responsible  for  upper  respiratory
tract infections
The  results,  expressed  as  percentage  reduction  [(T  —  E)/T],
are  presented  in  Table  3.
The  results  obtained  in  artiﬁcial  saliva  showed  percent-
age  reductions  greater  than  90%  after  only  5  min  of  contact
with  the  highest  concentration  (90%)  and  greater  than  99%
for  ﬁve  of  the  six  microorganisms  tested  when  with  the  50%
solution.  The  limiting  microorganism  was  S.  aureus.
When  the  stock  solution  was  diluted  to  50%  (simulation  of
dissolution  in  the  mouth)  and  after  3  h  of  contact,  an  intense
bactericidal  activity  (>  4  log  reduction)  was  observed  for  the
6  test  microorganisms  and  the  bactericidal  activity  was  still
detectable  in  relation  to  four  microorganisms  with  the  10%
solution.
The  results  obtained  on  the  H1N1  strain  indicate  reduc-
tions  greater  than  99%  (>  2  log)  in  the  presence  of  80%  and
w
S
o
l0%  solutions  for  a  contact  time  of  5  min.  A  greater  than
9.99%  reduction  (>  4 log)  was  observed  at  the  50%  concen-
ration  with  a  3-hour  contact  time.
The  antiviral  activity  (greater  than  99%  reduction)  was
aintained  with  the  10%  solution  by  increasing  the  contact
ime  to  three  hours.
ntibacterial  activity  in  relation  to  resident  ﬂora
aximum  values  of  MID  and  MBD  (dilutions  of  stock  solution)
ere  1/252  and  1/128,  respectively,  for  all  microorganisms
ested.
These  results  indicate  a  signiﬁcant  and  homogeneous
ntibacterial  activity  on  all  microorganisms  tested,  both
ram+  and  Gram− species.
iscussion
any  treatments  and  recommendations  are  considered  to
e  effective  in  the  treatment  of  sore  throat  and  anti-
nﬂammatory  and  analgesic  effects  play  a  considerable  role
n  the  treatment  of  these  diseases,  whether  or  not  they
re  due  to  infection.  For  example,  honey  has  a  recognized
fﬁcacy  as  a systemic  antitussive  [15]  related  to  its  antimi-
robial  and  healing  properties.  The  type  of  antibacterial
ctivity  observed  in  various  in  vitro  studies  corresponds  to
rowth  inhibition  [16,17]  and  is  therefore  lower  than  the
actericidal  effect  observed  with  an  antiseptic,  although
his  effect  cannot  be  dissociated  from  the  osmotic  and
etergent  effects  attributed  to  honey.
Several  recent  clinical  studies  have  tested  the  value
f  antiseptic  spray  solutions  or  lozenges  in  the  adjuvant
reatment  of  viral  and  bacterial  pharyngitis  and  sore  throat
10—12]. In  these  studies,  chlorhexidine,  an  antiseptic
gent,  was  associated  with  an  anti-inﬂammatory/analgesic
gent  in  a  spray  formulation.  Cingi  et  al.  [10,11]  conducted
lacebo-controlled  studies  in  patients  treated  with  peni-
illin  for  streptococcal  infections  or  paracetamol  for  viral
haryngitis.  In  both  studies,  the  evaluation  was  based  on
mprovement  of  the  patient’s  clinical  signs  and  quality  of
ife.  After  7  days  of  treatment,  the  authors  reported  a  signiﬁ-
ant  improvement  of  clinical  signs  in  both  types  of  infections
nd  a  signiﬁcant  improvement  of  quality  of  life  in  patients
ith  viral  infections  treated  with  the  spray.  The  study  by
chapowal  et  al.  [12]  compared  two  oral  sprays,  including
ne  spray  containing  a  combination  of  chlorhexidine  and
idocaine  in  the  treatment  of  cough.  The  authors  reported  a
192  C.  Michel  et  al.
Table  2  Test  strains  representative  of  upper  respiratory  tract  pathogens  and  culture  conditions  for  determination  of  antibac-
terial activity.
Strains  Medium  (MID)  Medium  (MBD)  Incubation  conditions
Streptococcus  milleri  Isolate  1  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C
Streptococcus milleri  Isolate  2  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C
Streptococcus milleri  Isolate  3  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C
Streptococcus mitis  CIP  103335  T  MH  +  10%  FCS  COS  5%  CO2 36  ±  1 ◦C
Streptococcus  mitis  Isolate  1  MH  +  10%  FCS  COS  5%  CO2 36  ±  1 ◦C
Streptococcus  mitis  Isolate  2 MH  +  10%  FCS  COS  5%  CO2 36  ±  1 ◦C
Streptococcus  oralis  CIP  102922  T MH  MH  5%  CO2 36  ±  1 ◦C
Streptococcus  oralis  Isolate  1 MH  MH  5%  CO2 36  ±  1 ◦C
Streptococcus  salivarius  CIP  102503 MH  MH  Aerobic  36  ±  1 ◦C
Streptococcus  salivarius  Isolate  1  MH  MH  Aerobic  36  ±  1 ◦C
Streptococcus  sanguinis  CIP  55128  MH  +  10%  FCS  COS  5  %  CO2 36  ±  1 ◦C
Streptococcus sanguinis  Isolate  1  MH  +  10%  FCS  COS  5  %  CO2 36  ±  1 ◦C
Streptococcus sanguinis  Isolate  2  MH  +  10%  FCS  COS  5%  CO2 36  ±  1 ◦C
Lactobacillus  lactis  Isolate  1  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C *
Lactobacillus  salivarius  CIP  103140  T  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C *
Lactobacillus  acidophilus  CIP  7613  T  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C *
Lactobacillus  acidophilus  Isolate  1  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C *
Lactobacillus  acidophilus  Isolate  2  MH  +  10%  FCS  COS  Anaerobic  36  ±  1 ◦C *
Moraxella  lincolnii  CIP  103802  T  MH  +  10%  FCS  COS  Aerobic  30  ±  1 ◦C *
Staphylococcus  epidermidis  CIP  6821  MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcus  epidermidis  CIP  8155  T  MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcu  epidermidis  Isolate  1  MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcu  epidermidis  Isolate  2 MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcus  epidermidis  Isolate  3  MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcu  epidermidis  Isolate  4  MH  MH  Aerobic  36  ±  1 ◦C
Staphylococcus  epidermidis  Isolate  5  MH  MH  Aerobic  36  ±  1 ◦C
Rothia mucilaginosa  CIP  7114 MH  MH  Aerobic  36  ±  1 ◦C *
Corynebacterium  imitans  CIP  105130 MH  +  10%  FCS COS  Aerobic  36  ±  1 ◦C
Neisseria cinerea  CIP  7316  T MH  +  10%  FCS  COS  Aerobic  36  ±  1 ◦C
Haemophilus  parainﬂuenzae  CIP  102513 MH  +  10%  FCS  +  1%  PV Ch.  H  5%  CO2 36  ±  1 ◦C
MH: Muller-Hinton (Biomérieux); FCS: Foetal calf serum (Lonza); COS: Columbia agar + 5% sterile sheep blood (Biomérieux); Ch. H:
eux).
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Reading after 24 hours of incubation, except for (*): reading after
igniﬁcant  improvement  (greater  than  50%  reduction  of  all
ymptoms)  in  57.8%  of  cases  (154  patients)  after  three  days
f  treatment  at  the  dosage  of  two  puffs  10  times  daily.  None
f  these  studies  evaluated  the  antimicrobial  efﬁcacy  of  the
est  formulations,  which  can  be  a  difﬁcult  procedure  in  vivo,
specially  when  based  on  saliva  counts,  due  to  modiﬁca-
ions  of  saliva  volume  and  ﬂow  related  to  the  use  of  sprays
r  lozenges.  The  present  study  was  therefore  designed  to
etermine  the  short-term  (5  min)  and  long-term  (3  h)  in  vitro
actericidal  and  virucidal  efﬁcacy  of  Drill® lozenges  in  order
o  conﬁrm  the  potential  value  of  the  combination  of  an
ntimicrobial  agent  and  an  analgesic  in  the  treatment  of
pper  respiratory  tract  infections.
Chlorhexidine  is  a  reference  antiseptic  used  on  the  skin
nd  mucous  membranes,  especially  in  the  mouth.  Recent
odiﬁcations  of  legislation  and  guidelines  [4—6]  concern-
ng  the  use  of  topical  antimicrobial  treatment  now  require
ormal  demonstration  of  the  value  of  chlorhexidine  formula-
ions  in  the  treatment  of  upper  respiratory  tract  infections.
his  study  was  conducted  in  the  context  of  this  approach.
valuation  of  the  bactericidal  activity  of  Drill® on  bacte-
ia  considered  to  be  pathogenic  in  the  upper  respiratory
e
c
s
nurs of incubation.
ract  indicated  a  rapid  action  of  the  concentrated  product
90%  stock  solution),  even  in  the  presence  of  artiﬁcial  saliva
hat  could  interfere  with  the  antiseptic  activity  of  chlorhex-
dine.  This  activity  persisted  over  time,  even  after  dilution
o  10%.  The  observed  bactericidal  activity  corresponded
o  published  data  concerning  the  spectrum  of  chlorhexi-
ine  that  includes  Gram+  and  Gram− bacteria  [18—20].  This
omogeneous  antibacterial  activity  was  associated  with  an
ntiviral  activity  in  relation  to  the  inﬂuenza  A  virus  (H1N1),
elated  to  the  recognized  virucidal  activity  of  chlorhexidine
n  enveloped  viruses  [21].
A  global  evaluation  of  the  antibacterial  activity  in  rela-
ion  to  the  resident  ﬂora  of  the  upper  respiratory  tract  was
onducted  in  support  of  the  indication  of  Drill® in  upper
espiratory  tract  infections  such  as  sore  throat.  This  study
onﬁrmed  the  value  of  using  an  antiseptic  versus  antibi-
tics,  as  chlorhexidine  is  characterized  by  a  non-speciﬁc
echanism  of  action  related  to  a  combination  of  cellular
ffects  (membrane  disorganization,  coagulation  of  intra-
ellular  proteins,  etc.)  resulting  in  a  broad  antimicrobial
pectrum  [18—20]. The  results  of  this  study  indicate  a
on-selective  activity,  which  therefore  limits  the  risk  of
Activity  of  Drill  lozenges  on  tne  main  ENT  microorganisms  
Table  3  Percentage  reduction  observed  on  the  main  bacte-
ria responsible  for  upper  respiratory  tract  infections  and  on
the H1N1  inﬂuenza  virus,  according  to  the  dilution  of  the
test product  and  the  contact  time  (5  min  or  3  h).
5  minutes  3  hours
S.  aureus  90  %  >  90  %
50  %  <  90  %
—
—
50  %  >  99.999  %
10  %  <  90  %
S. pneumoniae  90  %  >  99.99  %
50  %  >  99.99  %
—
—
50  %  >  99.99  %
10  %  >  99.99  %
S. pyogenes  90  %  >  99.99  %
50  %  >  99.99  %
—
—
50  %  >  99.999  %
10  %  <  90  %
F. nucleatum  90  %  >  99.999  %
50  %  >  99.99  %
—
—
50  %  >  99.999  %
10  %  >  99.99  %
H. inﬂuenzae  90  %  >  99.999  %
50  %  >  99.999  %
—
—
50  %  >  99.999  %
10  %  >  99.9  %
B. catarrhalis  90  %  >  99.99  %
50  %  >  99  %
—
—
50  %  >  99.999  %
10  %  >  99.999  %
H1N1 virus  80%  >  99% —
[
[
[
[
[
[
[
[
[
[
[50%  >  99%
—
50%  >  99.99%
10%  >  99%
disturbing  the  equilibrium  of  the  resident  ﬂora.  No  resis-
tance  was  observed  for  any  of  the  strains  tested.
Conclusion
All  of  these  results  appear  to  corroborate  current  guidelines
and  emphasize  the  value  of  this  approach  to  the  treat-
ment  of  upper  respiratory  tract  infections  using  lozenges
containing  a  combination  of  topical  antiseptic  and  an
anti-inﬂammatory/analgesic.  This  dosage  form  allows  easy
management  and  especially  potential  maintenance  of  effec-
tive  doses  at  the  site  of  the  infection.  Complementary  in  vivo
trials,  especially  comprising  treatment  follow-up,  should  be
conducted  to  conﬁrm  the  efﬁcacy  and  absence  of  destabi-
lization  of  the  endogenous  ﬂora  under  conditions  of  good
use.
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